Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Pol

Showing results (31-40 of 62) with videos related to

Pageof 7
Sort By:
Journal for Immunotherapy of Cancer|June 6, 2025
Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockadeLiwei Zhao, Peng Liu, Allan Sauvat, et al.
Oncoimmunology|July 3, 2015
Trial Watch: Peptide-based anticancer vaccinesJonathan Pol, Norma Bloy, Aitziber Buqué, et al.
Oncoimmunology|May 8, 2015
Trial watch: Tumor-targeting monoclonal antibodies for oncological indicationsErika Vacchelli, Jonathan Pol, Norma Bloy, et al.
Oncoimmunology|August 7, 2014
Trial Watch:: Oncolytic viruses for cancer therapyJonathan Pol, Norma Bloy, Florine Obrist, et al.
The EMBO Journal|June 8, 2018
Metabolic vulnerability of cisplatin-resistant cancersFlorine Obrist, Judith Michels, Sylvere Durand, et al.
Blood|January 18, 2013
Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8(+) T-cell recall responsesLiang Zhang, Byram W Bridle, Lan Chen, et al.
Oncoimmunology|July 3, 2015
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapyJonathan Pol, Erika Vacchelli, Fernando Aranda, et al.
Oncoimmunology|May 31, 2019
Tumor lysis with LTX-401 creates anticancer immunityWei Xie, Laura Mondragón, Brynjar Mauseth, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 9, 2013
HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapyByram W Bridle, Lan Chen, Chantal G Lemay, et al.
Oncoimmunology|May 6, 2015
Trial watch: Dendritic cell-based anticancer therapyNorma Bloy, Jonathan Pol, Fernando Aranda, et al.
Pageof 7

Showing results (31-40 of 62) with videos related to

Sort By:
Pageof 7
Journal for Immunotherapy of Cancer|June 6, 2025
Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockadeLiwei Zhao, Peng Liu, Allan Sauvat, et al.
Oncoimmunology|July 3, 2015
Trial Watch: Peptide-based anticancer vaccinesJonathan Pol, Norma Bloy, Aitziber Buqué, et al.
Oncoimmunology|May 8, 2015
Trial watch: Tumor-targeting monoclonal antibodies for oncological indicationsErika Vacchelli, Jonathan Pol, Norma Bloy, et al.
Oncoimmunology|August 7, 2014
Trial Watch:: Oncolytic viruses for cancer therapyJonathan Pol, Norma Bloy, Florine Obrist, et al.
The EMBO Journal|June 8, 2018
Metabolic vulnerability of cisplatin-resistant cancersFlorine Obrist, Judith Michels, Sylvere Durand, et al.
Blood|January 18, 2013
Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8(+) T-cell recall responsesLiang Zhang, Byram W Bridle, Lan Chen, et al.
Oncoimmunology|July 3, 2015
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapyJonathan Pol, Erika Vacchelli, Fernando Aranda, et al.
Oncoimmunology|May 31, 2019
Tumor lysis with LTX-401 creates anticancer immunityWei Xie, Laura Mondragón, Brynjar Mauseth, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 9, 2013
HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapyByram W Bridle, Lan Chen, Chantal G Lemay, et al.
Oncoimmunology|May 6, 2015
Trial watch: Dendritic cell-based anticancer therapyNorma Bloy, Jonathan Pol, Fernando Aranda, et al.
Pageof 7